tiprankstipranks
Evgen Pharma PLC (GB:TCF)
LSE:TCF
Holding GB:TCF?
Track your performance easily

Evgen Pharma (TCF) Income Statement

1 Followers

Evgen Pharma Income Statement

Last quarter (Q2 2023), Evgen Pharma's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Evgen Pharma's net income was £―. See Evgen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 24Mar 23Mar 22Mar 21Mar 20
Total Revenue
-£ 396.00K£ 442.00K-£ 194.00K-
Cost of Revenue
------
Gross Profit
-£ 396.00K£ 442.00K---
Operating Expense
-£ 3.96M£ 5.51M£ 3.19M£ 3.40M£ 3.15M
Operating Income
-£ -3.56M£ -5.07M-£ -3.20M£ -3.15M
Net Non Operating Interest Income Expense
--£ 98.00K£ 24.00K--
Other Income Expense
------
Pretax Income
-£ -3.57M£ -5.01M£ -3.17M£ -3.21M£ -3.17M
Tax Provision
-£ -429.00K£ -963.00K£ -439.00K£ -539.00K£ -451.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -3.14M£ -4.04M-£ -2.67M£ -2.71M
Basic EPS
-£ -0.01£ -0.01£ -0.99£ -0.02£ -0.02
Diluted EPS
-£ -0.01£ -0.01£ -0.99£ -0.02£ -0.02
Basic Average Shares
-£ 274.89M£ 274.89M£ 274.89M£ 149.20M£ 131.23M
Diluted Average Shares
-£ 274.89M£ 274.89M£ 274.89M£ 149.20M£ 131.23M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ 3.96M£ 5.51M-£ -3.40M£ -3.15M
Net Income From Continuing And Discontinued Operation
-£ -3.14M£ -4.04M£ -2.73M£ -2.67M£ -2.71M
Normalized Income
-£ -4.00M£ -5.97M£ -3.61M£ -3.75M£ -3.62M
Interest Expense
------
EBIT
-£ -3.57M£ -5.01M£ -3.17M£ -3.21M£ -3.17M
EBITDA
-£ -3.56M£ -4.99M£ -3.15M£ -3.21M£ -3.17M
Currency in GBP

Evgen Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis